Sherpa Healthcare Partners
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Link Cell Therapies | Sep 2026Participated | $30 MSeries A | |
Avisi Technologies | Feb 2026Participated | $11 MSeries A | |
Spiro Medical | Jan 2026Led | $67 MSeries A | |
PAQ Therapeutics | May 2025Participated | $39 MSeries B | |
ZWI Therapeutics, Inc. | Jan 2024Participated | $10 MSeries A | |
GRIT Biotechnology | Sep 2023Participated | $60 MSeries B | |
Neukio Biotherapeutics | Sep 2022Participated | $50 MSeries A | |
Leadsynbio | Mar 2022Led | $63 MSeries C | |
Hong Kong Asia Heart Centre | Feb 2022Participated | $400 MSeries D | |
Fuse Biotherapeutics | Nov 2021Participated | $10 MSeed | |
BAKX Therapeutics | Nov 2021Participated | $25 MSeries A | |
Alamar Biosciences | Sep 2021Led | $80 MSeries B | |
Link Cell Therapies | Sep 2026Participated | $30 MSeries A | |
Avisi Technologies | Feb 2026Participated | $11 MSeries A | |
Spiro Medical | Jan 2026Led | $67 MSeries A | |
PAQ Therapeutics | May 2025Participated | $39 MSeries B | |
ZWI Therapeutics, Inc. | Jan 2024Participated | $10 MSeries A | |
GRIT Biotechnology | Sep 2023Participated | $60 MSeries B | |
Neukio Biotherapeutics | Sep 2022Participated | $50 MSeries A | |
Leadsynbio | Mar 2022Led | $63 MSeries C | |
Hong Kong Asia Heart Centre | Feb 2022Participated | $400 MSeries D | |
Fuse Biotherapeutics | Nov 2021Participated | $10 MSeed | |
BAKX Therapeutics | Nov 2021Participated | $25 MSeries A | |
Alamar Biosciences | Sep 2021Led | $80 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 1 |
| Series A | 2 | 6 |
| Series B | 3 | 6 |
| Series C+ | 1 | 4 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '19 | 1 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 1 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 1 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 1 |
| May '21 | 2 |
| Jun '21 | 0 |
| Jul '21 | 2 |
| Aug '21 | 0 |
| Sep '21 | 1 |
| Oct '21 | 0 |
| Nov '21 | 2 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 1 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 1 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 1 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 1 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 23 |
| Manufacturing | 2 |
| Travel & Hospitality | 1 |
| Space & Frontier Tech | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 1 |
| $10M-$25M | 3 |
| $25M-$50M | 5 |
| $50M-$100M | 10 |
| $100M-$250M | 3 |
| $250M-$500M | 1 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| China | 12 |
| United States | 10 |
| Hong Kong | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Lilly Asia Ventures | 4 |
| Hongshan Capital Group (Sequoia Capital China) | 3 |
| Matrix Partners China | 3 |
| Cormorant Asset Management | 2 |
| Decheng Capital | 2 |
| Huagai Capital | 2 |
| IDG Capital | 2 |
| Johnson & Johnson Innovation | 2 |
| Loyal Valley Capital | 2 |
| MRL Ventures Fund | 2 |
| Samsara BioCapital | 2 |
| SDIC Fund | 2 |
| 3E Bioventures Capital | 1 |
| 3H Health Investment | 1 |
| 5Y Capital | 1 |
| 8VC | 1 |
| AB Magnitude Ventures Group | 1 |
| Accanto Partners | 1 |
| Andera Partners | 1 |
| Ascendis Pharma | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 6 | 26% |
| Participating | 17 | 74% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 50% |
| Co-led | 3 | 50% |
Team
Founder & Managing Partner
Vice President
Co-Founder & Managing Partner
Managing Director
Co-Founder/Managing Partner
Investment Associate
Vice President